Welcome to our dedicated page for Allurion Technologies news (Ticker: ALUR), a resource for investors and traders seeking the latest updates and insights on Allurion Technologies stock.
Allurion Technologies, Inc. (NYSE: ALUR) is a pioneering medical device company committed to combating obesity through innovation. The company offers a comprehensive weight loss platform known as the Allurion Program, which includes the world's first and only swallowable, procedure-less intragastric balloon designed for weight loss. This unique solution, the Allurion Balloon, is delivered without the need for surgery, endoscopy, or anesthesia, making it a convenient and less invasive option for patients.
The Allurion Program is further enhanced by the Allurion Virtual Care Suite (VCS), a suite of AI-powered tools that aid in remote patient monitoring, proprietary behavior change programs, secure messaging, and video telehealth services. The virtual suite also includes the Allurion Mobile App for consumers, the Allurion Connected Scale, and Allurion Insights for healthcare providers featuring the Iris AI Platform. These components work synergistically to ensure a comprehensive and personalized weight loss journey for patients.
Recent achievements by Allurion include a significant partnership with the Somerset NHS Foundation Trust, making it the first NHS trust to introduce the Allurion Gastric Balloon. This partnership aims to provide rapid, effective weight loss solutions to those most in need, particularly patients with high BMIs who require rapid weight loss to qualify for lifesaving surgeries.
Clinical data supports the efficacy and safety of the Allurion Program, with studies showing an average weight loss of 10-15% of body weight over approximately four months. Impressively, around 96% of this weight loss can be sustained one year after the balloon passes. The program has demonstrated particular effectiveness in patients with higher BMIs, with weight loss percentages reaching up to 20% over six months for those with a BMI over 40.
Financially, Allurion has shown robust growth and potential, evidenced by a 30% increase in procedural volume, reflecting strong demand for their innovative solutions. The company's commitment to expanding its offerings and its strategic partnerships aims to address the growing obesity epidemic, which imposes significant financial burdens on healthcare systems worldwide.
Allurion's leadership team, led by Founder and CEO Dr. Shantanu Gaur, continues to drive the company forward with a clear vision and strategic direction, focusing on expanding their global footprint and enhancing patient outcomes through continuous innovation and partnerships.
Allurion Technologies (NYSE: ALUR) announced three presentations at the European Congress on Obesity (ECO) held from May 12-15, 2024, in Venice, Italy. The presentations highlighted data from a study involving 712 patients across six obesity centers, demonstrating an average total body weight loss (TBWL) of 14.1% in four months, with 70% of the weight loss from fat mass and only 30% from lean body mass. The Allurion Program, which includes the Allurion Balloon and Virtual Care Suite, aims to preserve lean body mass during weight loss. Additionally, previous studies showed that more intensive programs led to 100% fat mass-derived weight loss without muscle mass loss. The presentations also covered behavior change coaching and the positive impact of GLP-1s on the program.
Allurion Technologies (NYSE: ALUR) announced its Q1 2024 financial results with a revenue of $9.4 million, a 14% increase from Q4 2023 but a decrease from $14.1 million in Q1 2023. Procedural volume rose 12% year-over-year and 22% sequentially. Cash burn decreased to $8.4 million from $22 million in Q4 2023. Notable developments include treating the first NHS patient with the Allurion Balloon, launching the VCS digital platform in the U.S., and securing $48 million in financing. Operating expenses were reduced significantly, but a year-over-year revenue decline and lower gross profit margins were noted.
Allurion Technologies, Inc. (NYSE: ALUR) announced three scientific presentations at IFSO-European Chapter 2024, highlighting 80% sustained weight loss at three years with the Allurion Program and successful outcomes of an AI-powered conversational agent for obesity treatment. The data showcased positive long-term weight maintenance results and patients' healthier eating habits post-program. Additionally, the innovative AI-powered weight loss coach, Coach Iris, received positive feedback for its personalized, trustworthy, and empathetic approach.
Allurion Technologies, Inc. announced preliminary first quarter 2024 results, with quarter-over-quarter revenue growth, procedural volume growth, and a significant decrease in cash burn. The company expects revenue between $9.2 million to $9.3 million, 12%-13% higher than the fourth quarter of 2023, procedural volume growth of 22%, and reduced cash burn of $8 million to $9 million. Allurion remains optimistic about future growth and business opportunities.
FAQ
What is the current stock price of Allurion Technologies (ALUR)?
What is the market cap of Allurion Technologies (ALUR)?
What is the Allurion Program?
How does the Allurion Gastric Balloon work?
What makes the Allurion Program unique?
Is the Allurion Balloon safe?
Who can benefit from the Allurion Program?
What recent achievements has Allurion accomplished?
What are the components of the Allurion Virtual Care Suite?
How effective is the Allurion Program?
What support does Allurion offer to healthcare providers?
What is the financial outlook for Allurion?
